About 30 results found for searched term "STING-IN-2" (0.134 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M14125 | STING-IN-2 | STING |
| STING-IN-2 (C-170) is a potent and covalent STING inhibitor. STING-IN-2 efficiently inhibits both mouse STING (mmSTING) and human STING (hsSTING). STING-IN-2 can be used for autoinflammatory disease research. | ||
| M3561 | Geldanamycin | HSP |
| NSC 122750; GDM | ||
| Geldanamycin is a natural existing HSP90 inhibitor with Kd of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association. | ||
| M15034 | Recombinant Human CD25/IL-2Rα Fc Chimera (HEK 293) | Cytokines and Growth Factors |
| CD25 antigen; CD25; IDDM10 | ||
| The IL-2 receptor system consists of three non-covalently linked subunits termed IL-2Rα, IL-2Rβ, and IL-2Rγ. The IL-2Rα is a type I transmembrane protein consisting of a 219 amino acid (a.a.) extracellular domain, a 19 a.a. transmembrane domain and a 13 a.a. intracellular domain, which is not involved in the transduction of IL-2 signal. | ||
| M14876 | THAL-SNS-032 | PROTAC |
| THAL-SNS-032 is a selective CDK9 degrader PROTAC consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN). | ||
| M21434 | INY-03-041 | PROTAC |
| INY-03-041 is an effective and highly selective Protac-based pan-Akt degradation consisting of GDC-0068, an ATP-competitive AKT inhibitor conjugated to lenalidomide (Cereblon ligand). INY-03-041 inhibited AKT1, AKT2 and AKT3 with IC50 values of 2.0 nM, 6.8 nM and 3.5 nM, respectively. | ||
| M21562 | Zymosan A (from Saccharomyces cerevisiae) | TLR |
| Zymosan A can increase the level of cyclin D2, suggesting the role of cyclin D2 in macrophage activation and proliferation. After injection of galactosamine, it aggravated acute liver injury, suggesting that some non-parenchymal cells besides Kupfer's cells were involved in fermentase action. | ||
| M21614 | 2'3'-cGAMP | Metabolite/Endogenous Metabolite |
| 2'-3'-cyclic GMP-AMP;2',3'-cGAMP | ||
| 2'3'-cGAMP (2'-3'-cyclic GMP-AMP) is a endogenous cGAMP in mammalian cells. 2'3'-cGAMP binds to STING with a high affinity and is a potent inducer of interferon-β (IFNβ). 2'3'-cGAMP is produced in mammalian cells in response to DNA in the cytoplasm. | ||
| M21652 | SN-001 | STING |
| SN001 | ||
| SN-001 is a STING inhibitor with an IC50 of 3.82 μM. SN-001 targets the cyclic dinucleotide binding pocket of human STING. | ||
| M24707 | Indusatumab vedotin | Drug-Linker Conjugates for ADC |
| MLN0264; TAK-264 | ||
| Indusatumab vedotin (MLN-0264; AKT-264) is an antibody-drug conjugate (ADC) consisting of the human anti-guanylate cyclase C (GCC) antibody linked to a microtubule-disruptor Monomethyl auristatin . Indusatumab vedotin has anti-proliferative effects on pancreas cancer cell lines. Indusatumab vedotin arrests cell cycle at G2/M phase, and induces apoptosis. | ||
| M24863 | Bifikafusp alfa | Others |
| L19-IL2 | ||
| Bifikafusp alfa (L19-IL2) is an immunotherapy fusion protein consisting of human L19 antibodies fused to the human cytokine interleukin 2 (IL2).Bifikafusp alfa is specific to the EDB domain of fibronectin. Bifikafusp alfa has anticancer activity. | ||
| M24939 | Inbakicept | Fusion Proteins |
| ALT-803; N-803 | ||
| Inbakicept is an IL-15 receptor activator, consisting of IL-15 mutant and IL-15Rα-Fc fusion. Inbakicept magnifies anti-CD20 mAb-mediated NK-cell responses and antibody-dependent cellular cytotoxicity (ADCC). Inbakicept also increases degranulation, IFNγ production in cells. | ||
| M25118 | Farletuzumab ecteribulin | Drug-Linker Conjugates for ADC |
| MORAb-202 | ||
| Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a drug-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. | ||
| M25226 | Albinterferon alfa-2B | Others |
| alb-IFN | ||
| Albinterferon alfa-2B (alb-IFN) is a recombinant protein consisting of interferon alfa-2b genetically fused to human albumin. Albinterferon alfa-2B can be used for the research of chronic hepatitis C. | ||
| M27659 | (+)-Tetrabenazine | Monoamine Transporter |
| (+)-TBZ; (3R,11bR)-TBZ; (3R,11bR)-Tetrabenazine | ||
| (+)-Tetrabenazine ((+)-TBZ; (3R,11bR)-TBZ; (3R,11bR)-Tetrabenazine) is a reversible inhibitor of vesicular monoamine transporter 2 (VMAT-2), inhibits transport by VMAT2 with 10-fold greater potency than transport by VMAT1. target: VMAT-2 In vitro: (+)-Tetrabenazine inhibit the activity of the transporter but appear to interact differently with the protein. [2] (+)-Tetrabenazine inhibits reserpine binding to the transporter, suggesting that the sites may interact in an allosteric manner. [1] In vivo: 0.9% saline (80%) and dimethylsulfoxide (DMSO) (20%). (+)-Tetrabenazine blocks dopamine (DA) storage and depletes striatal DA; (+)-Tetrabenazine was shown to induce tremulous jaw movements (TJMs) in rats and mice. The reference dose for administration is 2.0 mg/kg.[2] | ||
| M28645 | Azilsartan mepixetil | Angiotensin Receptor |
| Azilsartan mepixetil is the antagonist of angiotensin II receptor. Azilsartan mepixetil has stronger and longer blood pressure effect, more abvious and longer lasting heart rate lowering effect and high safety. Azilsartan mepixetil achieves ideal protective effect for heart and kidney functions. Azilsartan mepixetil has the potential for the research of hypertension, chronic heart failure and diabetic nephropathy (extracted from patent CN107400122A). | ||
| M29290 | STING agonist-4 | STING |
| STING agonist-4 is an stimulator of Interferon Genes (STING) receptor agonist with an apparent inhibitory constant (IC50) of 20 nM. STING agonist-4 is a two symmetry-related amidobenzimidazole (ABZI)-based compound to create linked ABZIs (diABZIs) with enhanced binding to STING and cellular function. | ||
| M29813 | PROTAC STING Degrader-1 | STING |
| PROTAC STING Degrader-1 (Compound SP23) is a STING PROTAC degrader with a DC50 of 3.2 μM. PROTAC STING Degrader-1 shwos anti-inflammatory activity. | ||
| M30761 | Fasitibant chloride hydrochloride | Bradykinin Receptor |
| MEN16132 | ||
| Fasitibant chloride hydrochloride (MEN16132) is a potent, selective, high affinity, and long-lasting nonpeptide bradykinin B2 (BK2) receptor antagonist. Fasitibant chloride hydrochloride has proinflammatory effects and can be used for the research of osteoarthritis and rheumatoid arthritis. | ||
| M30763 | Fasitibant free base | Bradykinin Receptor |
| Fasitibant (free base) is a potent, selective, high affinity, and long-lasting nonpeptide bradykinin B2 (BK2) receptor antagonist. Fasitibant (free base) has proinflammatory effects and can be used for the research of osteoarthritis and rheumatoid arthritis. | ||
| M40765 | Datopotamab deruxtecan | Others |
| Dato-DXd | ||
| Datopotamab deruxtecan is an antibody-coupled drug (ADC) consisting of a humanized, monoclonal antibody targeting human trophoblast cell surface glycoprotein antigen 2 (Trop2) conjugated to an innovative DNA topoisomerase I inhibitor (DXd) for use in studies related to non-small cell lung cancer (NSCLC). | ||
| M40970 | Hydroethidine | Fluorescent Dye |
| Hydroethidine is a peroxide indicator that freely enters cells and dehydrogenates into ethidium bromide and distinguishes between superoxide and H2O2, and can be used to identify proliferating and hypoxic cells in tumors (λex=520 nm, λem=600 nm). This product has been merged into M9696 | ||
| M42056 | STING agonist-8 dihydrochloride | STING |
| STING agonist-8 dihydrochloride is a potent STING agonist with an EC50 of 27 nM in THP1-Dual KI-hSTING-R232 cells. | ||
| M42058 | STING agonist-31 | STING |
| STING agonist-31 is a STING agonist, with EC50 values of 0.24 and 39.51 μM for h-STING and m-STING. | ||
| M42123 | JNK-IN-12 | JNK |
| JNK-IN-12 is a mitochondrial-targeted JNK inhibitor (IC50=66.3 nM), consisting of a mitochondrial-specific cell-penetrating peptide and a specific inhibitor of JNK, SP600125. | ||
| M42433 | PROTAC HK2 Degrader-1 | Others |
| PROTAC HK2 Degrader-1 is a PROTAC consisting of Lonidamine as a target protein Hexokinase 2 (HK2) inhibitor and Thalidomide as a CRBN ligand-linked PROTAC. | ||
| M45027 | trans-2-Hexen-1-ol | Others |
| (E)-Hex-2-en-1-ol belongs to the class of unsaturated alcohols consisting of a six-carbon chain with a double bond between carbon atoms 2 and 3 and a hydroxyl group attached to carbon atom 1. | ||
| M45063 | 2',3'-cGAMP sodium | Metabolite/Endogenous Metabolite |
| 2'-3'-cyclic GMP-AMP sodium | ||
| 2',3'-cGAMP sodium is an endogenous cGAMP in mammalian cells that binds STING with high affinity and is also a potent inducer of interferon-beta (IFNβ).2',3'-cGAMP sodium is produced in mammalian cells in response to DNA in the cytoplasm. | ||
| M52497 | β-Amyloid (13-27) | Amyloid |
| β-Amyloid (13-27) is a peptide consisting of amino acid of 13 to 27 of beta amyloid protein. | ||
| M55253 | SL-279252 | PD-1/PD-L1 |
| PD1-Fc-OX40L | ||
| SL-279252 (PD1-Fc-OX40L) is a hexameric, bi-functional fusion protein with an ECD of PD-1 (70 pM affinity to PD-L1) linked to the ECD of OX40L (324 pM affinity for OX40) through an Fc linker. SL-279252 exhibited linear PK at doses up to 3.0 mg/kg, and a greater than proportional increase in AUC was observed at 6.0 mg/kg suggesting potential receptor saturation. The preliminary half-life is approximately 23 hours. | ||
| M55364 | Recombinant Mouse IL-22 (HEK293, C-mFc) | Cytokines and Growth Factors |
| Interleukin-22 | ||
| Interleukin-22 (IL-22) is produced by normal mouse T cells upon Con A activation. Mouse IL-22 expression is also induced in various organs upon lipopolysaccharide injection, suggesting that IL-22 may be involved in inflammatory responses. IL22 has been shown to activate STAT-1 and STAT-3 in several hepatoma cell lines and up-regulate the production of acute phase proteins. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
